International guidelines for the management of pancreatic intraductal papillary mucinous neoplasms

Table 1 Summary of the Sendai Consensus Guidelines and Fukuoka Consensus Guidelines

Guideline	Criteria
SCG
MD-IPMN	MPD ≥ 10 mm
SCG+ve BD-IPMN	Size > 3 cm
	Size ≤ 3 cm with symptoms/mural nodules/MPD dilation (> 6 mm)/ positive cytology
FCG
High risk features	Proximal lesion with obstructive jaundice
	Enhancing nodules
	Dilated main duct (≥ 10 mm)
Worrisome risk features	Size ≥ 3 cm
	Pancreatitis
	Non-enhancing nodules
	Thickened, enhancing walls
	Dilated duct (5 to < 10 mm)
	Change in duct caliber with distal atrophy
	Lymphadenopathy

FCG: Fukuoka; SCG: Sendai Consensus Guidelines; MPD: Main pancreatic duct; MD-IPMN: Main-duct intraductal papillary mucinous neoplasm; BD-IPMN: Branch-duct intraductal papillary mucinous neoplasm.